Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2025; 17(3): 100342
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.100342
Resveratrol and pancreatic cancers: Questions and future perspectives
Olga A Sukocheva
Olga A Sukocheva, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide 5000, South Australia, Australia
Author contributions: Sukocheva OA conceived, designed, and drafted the submitted manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Olga A Sukocheva, PhD, Senior Scientist, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Port Road, Adelaide 5000, South Australia, Australia. olga.sukocheva@sa.gov.au
Received: August 14, 2024
Revised: November 20, 2024
Accepted: December 4, 2024
Published online: March 15, 2025
Processing time: 184 Days and 10.2 Hours
Core Tip

Core Tip: A promising new direction for the treatment of pancreatic cancer has been investigated and reported by Jiang et al. Using immunohistochemistry, the authors assessed pancreatic cancer tissues and detected the presence of senescent cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Following this, the authors observed the ability of the natural polyphenolic compound resveratrol to reverse the senescent CAF phenotype and inhibit pancreatic cancer progression in vitro and in vivo. This editorial assesses important aspects of the original article and discusses future perspectives of resveratrol-containing therapy.